OACS-3
Research type
Research Study
Full title
Obeticholic acid for the Amelioration of Cognitive Symptoms trial - 3
IRAS ID
1004317
Contact name
David Jones
Contact email
Sponsor organisation
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Eudract number
2020-004958-30
ISRCTN Number
ISRCTN98936300
Research summary
This research aims to see whether treatment with Obeticholic Acid improves cognitive and fatigue symptoms and whether it is safe and well tolerated in people with Parkinson’s (PwP). If the results from this small trial show that the treatment might be effective, it could lead to a larger clinical trial. \nThe development of memory and thinking problems in PwP is common, and has a profound effect on patients and carers. At present, there are little in the way of treatment options and no treatments that alter the progression of cognitive decline. There has been increasing interest in drugs used in other medical conditions that might also have an effect in Parkinson’s. One such drug is Obeticholic Acid, which has been used in liver disease (specifically in a disorder called Primary Biliary Cholangitis) and may improve cognition.\n\nUsing drugs that are already in clinical use for other conditions is an effective way to ensure patient benefit is seen in a timely manner. We know from other research that there might be a similar underlying mechanism of thinking problems in patients with both liver disease and Parkinson’s. If this study demonstrates some improvements in measurements, it will be a very exciting field of research where little treatment currently exists.
REC name
London - Hampstead Research Ethics Committee
REC reference
22/LO/0115
Date of REC Opinion
8 Mar 2022
REC opinion
Further Information Favourable Opinion